

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Docket No.

BMID9809US

Applicant(s): Dwulet et al.

Serial No.

09/901,996

Filing Date

July 10, 2001

Examiner

To Be Assigned

Group Art Unit

To Be Assigned

Invention: ENZYME/TAG BINDING AND DETECTION SYSTEM

I hereby certify that this Preliminary Amendment with Sequence Listing

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under

37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C.

20231-0001 on

February 13, 2002

(Date)

Melissa Watts

(Typed or Printed Name of Person Mailing Correspondence)

Melissa Watts

(Signature of Person Mailing Correspondence)

EL841987695US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

PATENT

Docket No. BMID 9809 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dwulet et al.

Application No.: 09/901,996

Group No.: Unknown

Filed: 7/10/2001

Examiner: Unknown

For: ENZYME/TAG BINDING AND DETECTION SYSTEM

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please enter the following amendments prior to examination of the above-referenced application:

IN THE SPECIFICATION:


Please omit the Sequence Listing filed contemporaneously with the above-mentioned patent application and insert the attached Sequence Listing in its place. By Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, the USPTO brought it to Applicants' attention that certain items were mistakenly designated "nucleotides" when they are, quite obviously, amino acids. Applicants believe the simplest method of correcting this mistake is to simply substitute the attached pages for the previously filed Sequence Listing.

The undersigned hereby states that the content of the Sequence Listing filed herewith (4 pages, numbered 1 to 4) and the computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same and contain no new matter. Also enclosed is a Checker 3.0 Verification Summary Report demonstrating that the Sequence Listing complies with the applicable rules, and a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid

Sequence Disclosures mailed on September 17, 2001.

Respectfully submitted,

Date: 2/12/02



Kenneth J. Waite, Reg. No. 45,189
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457
Telephone No.: (317) 521-3104
Facsimile No.: (317) 521-2883

\\RIDNFDAT5\VOL2\CORE\PLD\IDS\9600-9899\9809us\Preliminary Amendment.doc